FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 353:1410-1411 September 29, 2005 Number 13 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

RNA interference, which is mediated by small, double-stranded fragments of RNA called short interfering RNA (siRNA), is now a popular method to silence the expression of specific genes. It exploits the ability of the short, double-stranded fragment to abrogate the expression of the gene that shares its sequence and is useful not only as a basic research tool but also for drug-target validation. But the greatest hope for RNA interference lies in the potential use of siRNA oligonucleotides as drugs. The issue that has long bedeviled oligonucleotide-based therapies is how to deliver these agents to specific cellular or tissue targets. . . . [Full Text of this Article]

Source Information

From the Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland.

This article has been cited by other articles:

• Fredenburgh, L. E., Perrella, M. A., Mitsialis, S. A. (2007). The Role of Heme Oxygenase-1 in Pulmonary Disease. Am. J. Respir. Cell Mol. Bio. 36: 158-165 [Abstract] [Full Text]